Special Issue

Prevention, Early Detection, and Surgical Oncology in Hepatocellular Carcinoma, Pancreatic Cancer, and Gastrointestinal Cancer

Message from the Guest Editors

Early detection plays a crucial role in improving outcomes in hepatocellular carcinoma (HCC), pancreatic cancer, and gastrointestinal (GI) cancers. For HCC, liver resection or transplantation offers the best chance of long-term survival when the disease is detected early. Pancreatic cancer, often diagnosed at advanced stages, can be treated with surgical resection combined with neoadiuvant or adjuvant therapies to improve prognosis. In GI cancers, such as colorectal or gastric cancer, minimally invasive surgical techniques and enhanced recovery protocols have significantly improved patient outcomes. Interdisciplinary approaches integrating surgery into targeted therapies and immunotherapy are increasingly important in the management of these cancers. Continued research into early detection methods and precision oncology offers hope in terms of reducing mortality and enhancing quality of life in affected patients. We are particularly interested in manuscripts that explore early detection and the role of surgery in HCC, pancreatic cancer, and other gastrointestinal cancers.

Guest Editors

Dr. Mingyao Chen

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Medical University—Shuang Ho Hospital, New Taipei City 23561, Taiwan

Dr. Kuang-Chun Hu

Division of Gastroenterology, Department of Internal Medicine, MacKay Memorial Hospital, Taipei 104217, Taiwan

Deadline for manuscript submissions

31 August 2026



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/226592

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

